Sirolimus and gastrointestinal angiodysplasia: Can an established agent change the way gastrointestinal bleeding is managed?

doi:10.3748/wjg.v31.i41.113736

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 41

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (165)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=83

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=49

Publishing Process of This Article

Item

Count

Browse

Download

Sum=15

Nov 7, 2025 (publication date) through Nov 11, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Nov 7, 2025; 31(41): 113736
Published online Nov 7, 2025. doi: 10.3748/wjg.v31.i41.113736

Sirolimus and gastrointestinal angiodysplasia: Can an established agent change the way gastrointestinal bleeding is managed?

Robert Sean O'Neill, Jeyvin Nandakumaran, Robert Feller

Robert Sean O'Neill, Jeyvin Nandakumaran, Department of Gastroenterology and Hepatology, Campbelltown Hospital, Campbelltown 2560, New South Wales, Australia

Robert Sean O'Neill, South West Clinical School, The University of New South Wales, Sydney 2052, New South Wales, Australia

Robert Feller, Department of Gastroenterology and Hepatology, St Vincent's Hospital, Sydney 2010, New South Wales, Australia

Robert Feller, School of Medicine, The University of New South Wales, Sydney 2010, New South Wales, Australia

Author contributions: O’Neill RS and Nandakumaran J were responsible for the conception, writing, reviewing and submission of the manuscript; Feller R was responsible for supervision of manuscript preparation, conceptualization, reviewing and submission of the manuscript.

Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Robert Sean O'Neill, MBBS, Department of Gastroenterology and Hepatology, Campbelltown Hospital, Therry Road, Campbelltown 2560, New South Wales, Australia. rone1111@outlook.com

Received: September 2, 2025
Revised: September 23, 2025
Accepted: October 9, 2025
Published online: November 7, 2025
Processing time: 65 Days and 21.1 Hours

Core Tip

Core Tip: This article discussed the current treatment landscape of gastrointestinal angiodysplasia (GIAD) with a focus on pharmacological management rather than endoscopic management. It also examines the study by Sun et al, who demonstrated in their small single-centre study that sirolimus, a mammalian target of rapamycin inhibitor, reduced bleeding and transfusion needs while improving haemoglobin levels in GIAD patients.